ClinicalTrials.gg
Not yet recruitingNCT06231797Updated Feb 5, 2024

AI-ECG Screening for Left Ventricular Systolic Dysfunction

An observational study in Left Ventricular Systolic Dysfunction, sponsored by Seoul National University Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by Seoul National University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,530
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the current study is to verify the effectiveness of the artificial intelligence algorithm applied to the electrocardiogram as a potential screening tool for left ventricular systolic dysfunction.

Read the detailed description

The current investigators have developed an artificial intelligence (AI) algorithm based on 12-lead electrocardiogram (ECG) detecting left ventricular systolic dysfunction, through 364,845 ECGs from 148,547 patients. Then, when the model was tested retrospectively on 59,805 ECGs of 24,376 patients, the model performance expressed as an area under the receiver operating characteristic curve was 0.889 (95% CI 0.887-0.891).

The investigators are planning to prospectively validate the model's effectiveness as a potential screening tool for left ventricular systolic dysfunction.

02

Conditions studied

  • Left Ventricular Systolic Dysfunction
03

In context

Ventricular Dysfunction, Left

260 studies on the registry are indexed under Ventricular Dysfunction, Left; 57 are open to participants now.

This study's planned enrollment of 1,530 is above the median of 198 across 103 observational studies indexed under Ventricular Dysfunction, Left.

Browse Ventricular Dysfunction, Left studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients undergoing 12-lead ECG and transthoracic echocardiography in routine clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals or those whose legal representative agree to participate in the study, and sign the consent form
  • Can complete both 12-lead and transthoracic echocardiography

Exclusion criteria

Exclusion Criteria:

  • Individuals whose age is less than 18 year-old.
  • Individuals who do not agree to participate in the study
  • Patients who are unable to participate in clinical trials at the discretion of the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,530 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testAI algorithm conducted on 12-lead ECG and transthoracic echocardiography

    12-lead ECG is performed for each patient. For 12-lead ECG, AITIALVSD (AI algorithm) analysis will be performed through a separate server.

06

What researchers measure

Primary outcomes

  1. Area under the receiver operating characteristic curve (AUROC)

    AI model performance detecting LVSD, expressed as an AUROC. As a diagnostic assistance for LVSD, an ROC curve expressed as sensitivity to (1-specificity) will be presented, and the accuracy of prediction will be confirmed by calculating the AUROC, which is the area below.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Sensitivity

    AI model sensitivity detecting LVSD

    Time frame: Through study completion, an average of 1 year

  2. Specificity

    AI model sensitivity detecting patients with normal left ventricular systolic function

    Time frame: Through study completion, an average of 1 year

  3. Positive predictive value

    Positive predictive value in the recruited patient population

    Time frame: Through study completion, an average of 1 year

  4. Negative predictive value

    Negative predictive value in the recruited patient population

    Time frame: Through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kwon JM, Jo YY, Lee SY, Kang S, Lim SY, Lee MS, Kim KH. Artificial Intelligence-Enhanced Smartwatch ECG for Heart Failure-Reduced Ejection Fraction Detection by Generating 12-Lead ECG. Diagnostics (Basel). 2022 Mar 8;12(3):654. doi: 10.3390/diagnostics12030654. PubMed 35328207 ↗
  • Kwon JM, Kim KH, Jeon KH, Kim HM, Kim MJ, Lim SM, Song PS, Park J, Choi RK, Oh BH. Development and Validation of Deep-Learning Algorithm for Electrocardiography-Based Heart Failure Identification. Korean Circ J. 2019 Jul;49(7):629-639. doi: 10.4070/kcj.2018.0446. Epub 2019 Mar 21. PubMed 31074221 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06231797
Responsible party
Sponsor
First posted
Jan 30, 2024
Start date
Feb 1, 2024 (estimated)
Primary completion
Jul 10, 2024 (estimated)
Completion
Jul 10, 2025 (estimated)
Last update
Feb 5, 2024

Study contacts

Hak Seung Lee, MD
Contact
cardiolee@gmail.com
+1-771-216-0764
Seung-Pyo Lee, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion